Trial Outcomes & Findings for Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy (NCT NCT01328080)

NCT ID: NCT01328080

Last Updated: 2017-03-29

Results Overview

To determine if treatment of AKN with targeted ultraviolet B radiation will improve the clinical appearance of lesions.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

11 participants

Primary outcome timeframe

Baseline to Week 16

Results posted on

2017-03-29

Participant Flow

Participants were recruited from patient populations evaluated by the Johns Hopkins Department of Dermatology located at the Johns Hopkins Outpatient Center between April 2011 through April 2012. Participants were also be recruited from other patient populations at the Johns Hopkins Hospital through the use of advertisements.

Prior to UVB treatment,each subject's Minimal Erythema dose (MED) was determined. Exclusion criteria: photosensitive disorders,skin cancer,previous radiation therapy,use of photosensitizing drugs,lidocaine allergy,bleeding disorders,pregnancy,and lactation. Wash out: 4 weeks for antibiotics/corticosteroids, 6 months for oral isotretinoin.

Participant milestones

Participant milestones
Measure
Targeted UVB Phototherapy
All patients were randomly assigned to receive targeted UVB phototherapy 3 times a week for 16 weeks to either the right or the left side of the scalp. The untreated side served as an internal control until the end of week 8, after which both sides of the scalp were treated.
Overall Study
STARTED
11
Overall Study
COMPLETED
6
Overall Study
NOT COMPLETED
5

Reasons for withdrawal

Reasons for withdrawal
Measure
Targeted UVB Phototherapy
All patients were randomly assigned to receive targeted UVB phototherapy 3 times a week for 16 weeks to either the right or the left side of the scalp. The untreated side served as an internal control until the end of week 8, after which both sides of the scalp were treated.
Overall Study
Lost to Follow-up
5

Baseline Characteristics

Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Targeted UV-B
n=11 Participants
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
11 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
36.6 years
STANDARD_DEVIATION 6.6 • n=99 Participants
Sex: Female, Male
Female
0 Participants
n=99 Participants
Sex: Female, Male
Male
11 Participants
n=99 Participants
Region of Enrollment
United States
11 participants
n=99 Participants

PRIMARY outcome

Timeframe: Baseline to Week 16

To determine if treatment of AKN with targeted ultraviolet B radiation will improve the clinical appearance of lesions.

Outcome measures

Outcome measures
Measure
Targeted UVB Phototherapy
n=6 Participants
All patients were randomly assigned to receive targeted UVB phototherapy 3 times a week for 16 weeks to either the right or the left side of the scalp. The untreated side served as an internal control until the end of week 8, after which both sides of the scalp were treated.
Percentage Change in Total AKN Lesions From Baseline to Week 16.
49 percentage of lesion count reduction
Interval 29.0 to 61.0

Adverse Events

Targeted UVB Phototherapy

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Targeted UVB Phototherapy
n=11 participants at risk
All patients were randomly assigned to receive targeted UVB phototherapy 3 times a week for 16 weeks to either the right or the left side of the scalp. The untreated side served as an internal control until the end of week 8, after which both sides of the scalp were treated.
Skin and subcutaneous tissue disorders
erythema
18.2%
2/11 • Number of events 2 • 16 weeks

Additional Information

Ginette Okoye, MD, Director of Ethnic Skin Program

Johns Hopkins Dermatology

Phone: 410-502-7546

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place